Another study revealed that adenosine triphosphate (ATP) channels can control glioma radioresistance by adjusting ROS-induced ERK activation; thus, inhibiting ATP channels is a potential target for glioma therapeutic development (Huang et al., 2015). The gene discussed is MAPK1; the disease is central nervous system cancer.